Based on a study involving 198 patients with renal cell carcinoma (RCC) or metastatic melanoma (MM) treated with CTLA4 inhibitors, small bowel colitis was identified as the primary major toxicity, observed in 21% of patients 47. Here, CTLA4 is linked to renal cell carcinoma.